EXEL SEC-Einreichungen - Exelixis, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	254900PJQB59O2O95R37
CIK	939767

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Exelixis, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 29, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2026 EXELIXIS, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2026 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 29, 2026	EX-10.1	Exelixis, Inc. 2017 Equity Incentive Plan Adopted by the Board of Directors: February 23, 2017 Amended by the Compensation Committee: March 22, 2017 Approved by the Stockholders: May 24, 2017 Amended by the Company: December 18, 2017 Amended by the C Exhibit 10.1 Exelixis, Inc. 2017 Equity Incentive Plan Adopted by the Board of Directors: February 23, 2017 Amended by the Compensation Committee: March 22, 2017 Approved by the Stockholders: May 24, 2017 Amended by the Company: December 18, 2017 Amended by the Compensation Committee: March 18, 2020 Approved by the Stockholders: May 20, 2020 Amended by the Board of Directors: April 1, 2022 Approve
May 5, 2026	EX-99.1	Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Andrew Peters SVP, Strategy & Investor Relations Exelixis, Inc. 650-837-7248 [email protected] Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - -
May 5, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2026 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 3, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXE
May 5, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 05, 2026 EXELIXIS, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 05, 2026 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
April 17, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registran UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 15, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 15, 2026	DEF 14A	DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
February 10, 2026	EX-10.42	[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY 1. Exhibit 10.42 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. AMENDED AND RESTATED COLLABORATION AND LICENSE AGREEMENT This Amended and Restated Collaboration and License Agreement (the “Agreement”) is entered into as of December 17, 2025 (
February 10, 2026	10-K	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 2, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXIS,
February 10, 2026	EX-10.51	FOURTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT Exhibit 10.51 [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. FOURTH AMENDMENT TO COLLABORATION AND LICENSE AGREEMENT This Fourth Amendment to the Collaboration and License Agreement (the “Amendment”) is entered into as of November 21, 2025 (t
February 10, 2026	EX-21.1	SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 10, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2026 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2026 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 10, 2026	EX-99.1	Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the Fiscal Year 2025 - - Cabozantinib Franchise Achieved $2.123 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 [email protected] Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update - Total Revenues of $599 million for the Fourth Quarter of 2025, $2.320 billion for the
February 10, 2026	EX-10.21	January 22, 2013 Exhibit 10.21 January 22, 2013 Dear Brenda: We are proud to invite you to join our team. Our offer of employment is to join Exelixis, Inc. Your title will be that of Attorney II, in our Legal Services department reporting to Deborah Sim, Vice President, Legal Services & Senior Attorney in our Legal Services department. Other terms of employment include: Compensation: Your base salary will be five
February 10, 2026	EX-10.22	SEPARATION AGREEMENT Exhibit 10.22 CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [ * ], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SEPARATION AGREEMENT This Separation Agreement (together with all the exhibits and schedules attached hereto or thereto, the “Agreement”) is entered
January 12, 2026	EX-99.1	Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 – Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product rev Exhibit 99.1 Investor Contacts: Andrew Peters SVP, Strategy and Investor Relations Exelixis, Inc. 650-837-7248 [email protected] Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 [email protected] Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guid
January 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2026 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 11, 2026 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 7, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 4, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 4, 2025	EX-99.1	Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 milli
November 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 04, 2025 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 04, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
November 4, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2025 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 E
August 29, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2025 EXELIXIS, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 29, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
July 28, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2025 EXELIXIS, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 28, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
July 28, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2025 ☐ TRANSITION REPORT PURSUANT TO SE Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 4, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXEL
July 28, 2025	EX-99.1	Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 mill
June 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 EXELIXIS, INC. (Exac UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 28, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 13, 2025	EX-99.1	Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 million - - GAAP Diluted EPS of $0.55, Non-GAAP Diluted EPS of $0.62 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update - Total Revenues of $555.4 million, Cabozantinib Franchise U.S. Net Product Revenues of $513.3 milli
May 13, 2025	EX-10.1	Form of One-Time Performance-Based Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan Exhibit 10.1 Performance-Based Restricted Stock Unit Grant Notice Exelixis, Inc. 1851 Harbor Bay Parkway Alameda, CA 94502 Participant: Award #: Award Type: Plan: Shares Granted: Performance-Based Restricted Stock Units 2017 Equity Incentive Plan 1.Grant of Performance-Based Restricted Stock Unit Award Effective 03/31/2025 (“Date of Grant”), the Participant is hereby granted a Performance-Based Re
May 13, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2025 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 4, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXE
April 16, 2025	DEF 14A	DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14
April 16, 2025	ARS	ARS 2024 annual reportKey Corporate Highlights in cabozantinib franchise U.S. net product revenues in ﬁscal year 2024, an increase of 11% from 2023 cohesive Exelixis team united in our mission to help cancer patients recover stronger and live longer internal clinical programs with best- and/or ﬁrst-in-class potential in phase 1 development, with the potential for additional Investigational New Drug ﬁl
April 16, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
March 31, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 31, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 21, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2025 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 20, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 21, 2025	EX-99.1	Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - Completion of currently ongoing stock repurchase program expected in the second quarter of 2025 - Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces a Newly Authorized $500 Million Stock Repurchase Program - Completion of currently ongoing stock repurchase program expected in the second quarter of 2025 - ALAMEDA, C
February 11, 2025	EX-19.2	xelixis, Inc. Rule 10 Exhibit 19.2 Rule 10b5-1 Trading Plan Policy 1.Purpose This Rule 10b5-1 Trading Plan Policy (the “Trading Plan Policy”) has been established by the Board of Directors of Exelixis, Inc. (“Exelixis” or the “Company”) and sets forth procedures governing when the Company’s directors, executive officers and certain other employees designated by the Company’s Securities Compliance Committee (“SCC”) (ref
February 11, 2025	EX-21.1	Subsidiaries of Exelixis, Inc. Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company, LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 11, 2025	10-K	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 3, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXIS,
February 11, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 11, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 11, 2025	EX-99.1	Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for the Fiscal Year 2024 - - Cabozantinib Franchise Achieved $1.81 b Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Fourth Quarter and Fiscal Year 2024 Financial Results and Provides Corporate Update - Total Revenues of $567 million for the Fourth Quarter of 2024, $2.17 billion for
February 11, 2025	EX-19.1	xelixis, Inc. Insider Trading Polic Exhibit 19.1 Insider Trading Policy Exhibit 19.1 INSIDER TRADING POLICY INSIDER TRADING POLICY 1.PURPOSE Exelixis, Inc. (“Exelixis” or the “Company”) and its directors, employees and consultants are entrusted with important, confidential and proprietary information. Many of these persons are also investors in Exelixis and other companies with which Exelixis does business. Given the complexity of l
January 13, 2025	EX-99.1	Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial Guidance and Outlines Key Priorities and Milestones for 2025 – Cabozantinib franchise achieves approximately $1.805 billion in preliminary U.S. net product rev Exhibit 99.1 Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 [email protected] Exelixis Announces Preliminary Fiscal Year 2024 Financial Results, Provides 2025 Financial
January 13, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2025 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 29, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 27, 2024 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 27, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-3023
October 29, 2024	EX-99.1	Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million - - GAAP Diluted EPS of $0.40, Non-GAAP Diluted EPS of $0.47 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 [email protected] Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $539.5 million, Cabozantinib Franchise U.S. Net Product Revenues of $478.1 million -
October 29, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 29, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2024 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 14, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 15, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2024 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 15, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 6, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 06, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
August 6, 2024	S-8	As filed with the Securities and Exchange Commission on August 6, 2024 As filed with the Securities and Exchange Commission on August 6, 2024 Registration No.
August 6, 2024	EX-10.1	Exelixis, Inc. 2000 Employee Stock Purchase Plan Exelixis, Inc. 2000 Employee Stock Purchase Plan Adopted by Board of Directors: January 27, 2000 Approved by Stockholders: March 15, 2000 Amended by Board of Directors: January 28, 2005 Amendment Approved by Stockholders: April 22, 2005 Amended by Board of Directors: February 26, 2009 Amendment Approved by Stockholders: May 13, 2009 Amended by Compensation Committee: February 11, 2016 Amendment Ap
August 6, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Title of Securities to be Registered Fee Calculation Rule Amount Being Registered (1) Proposed Maximum Offering Price per Unit Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.
August 6, 2024	EX-99.1	Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 million - - GAAP Diluted EPS of $0.77, Non-GAAP Diluted EPS of $0.84 Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $637.2 million, Cabozantinib Franchise U.S. Net Product Revenues of $437.6 mill
August 6, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2024 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 28, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXE
June 3, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 30, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 21, 2024	LETTER	LETTER United States securities and exchange commission logo May 21, 2024 Christopher Senner Executive Vice President and Chief Financial Officer EXELIXIS, INC.
May 20, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 20, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 17, 2024	CORRESP	May 17, 2024 May 17, 2024 VIA EDGAR Vanessa Robertson, Staff Accountant Kevin Vaughn, Senior Associate Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
May 10, 2024	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 8, 2024	SC 13D/A	EXEL / Exelixis, Inc. / Farallon Capital Partners, L.P. Activist Investment SC 13D/A 1 exel13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Exelixis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30161Q104 (Cusip Number) Hannah E. Dunn Farallon Capital Management, L.L.C. One Maritime Plaza, Suite 2100 San Francisco, Califo
April 30, 2024	EX-3.2	Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc. Exhibit 3.2 STATE OF DELAWARE CERTIFICATE OF CHANGE OF REGISTERED AGENT AND/OR REGISTERED OFFICE The corporation organized and existing under the General Corporation Law of the State of Delaware, hereby certifies as follows: 1.The name of the corporation is EXELIXIS, INC. 2.The Registered Office of the corporation in the State of Delaware is changed to Corporation Trust Center, 1209 Orange Street,
April 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
April 30, 2024	EX-99.1	Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Restructuring Expenses of $32.8 million Recorded - - GAAP Dil Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Varant Shirvanian Director, Investor Relations Exelixis, Inc. 650-837-7917 [email protected] Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update - Total Revenues of $425 million, Cabozantinib Franchise U.S. Net Product Revenues of $379 million - - Re
April 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2024 ☐ TRANSITION REPORT PURSUANT TO Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 29, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EX
April 29, 2024	CORRESP	April 29, 2024 April 29, 2024 VIA EDGAR Vanessa Robertson, Staff Accountant Kevin Vaughn, Senior Associate Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
April 18, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 18, 2024	DEF 14A	DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin
April 8, 2024	CORRESP	April 8, 2024 April 8, 2024 VIA EDGAR Vanessa Robertson, Staff Accountant Kevin Vaughn, Senior Associate Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
March 29, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 EXELIXIS, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
March 19, 2024	LETTER	LETTER United States securities and exchange commission logo March 19, 2024 Christopher Senner Executive Vice President and Chief Financial Officer EXELIXIS, INC.
February 13, 2024	SC 13G/A	EXEL / Exelixis, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Exelixis Inc Title of Class of Securities: Common Stock CUSIP Number: 30161Q104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
February 13, 2024	SC 13G	EXEL / Exelixis, Inc. / RENAISSANCE TECHNOLOGIES LLC Passive Investment SC 13G 1 exel-13g20231231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 EXELIXIS, INC. - (Name of Issuer) Common Stock, $.001 Par Value per Share - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 19, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi
February 6, 2024	EX-10.23	Cash Compensation Information for Non-Employee Directors. Exhibit 10.23 CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS Exelixis, Inc. Cash Compensation for Non-Employee Directors Board of Directors Retainer Fee $60,000 Additional Chair Retainer Fee $35,000 Audit Committee Retainer Fee $15,000 Additional Chair Retainer Fee $15,000 Compensation Committee Retainer Fee $12,000 Additional Chair Retainer Fee $13,000 Nominating and Corporate Governanc
February 6, 2024	EX-21.1	Subsidiaries of Exelixis, Inc. Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company, LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 6, 2024	EX-10.18	Offer Letter Agreement, dated August 27, 2023, between Exelixis, Inc. and Amy C. Peterson Exhibit 10.18 August 17, 2023 Amy C. Peterson, M.D. Dear Amy, We are proud to invite you to join our team. Our offer of employment is to join Exelixis, Inc. (the “Company”). Your title will be that of Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, in our Development Administration department reporting to Michael Morrissey, President and Chief Executive
February 6, 2024	EX-99.1	Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update - Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Year 2023 - - Cabozantinib Franchise Achieved $1,629 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update - Total Revenues of $480 million for the Fourth Quarter of 2023, $1,830 million for the Fiscal Y
February 6, 2024	10-K	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 29, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXI
February 6, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
February 6, 2024	EX-97.1	Exelixis, Inc. Policy for Recoupment of Variable Compensation, amended and restated Exhibit 97.1 EXELIXIS, INC. POLICY FOR RECOUPMENT OF VARIABLE COMPENSATION Adopted February 28, 2019 Amended and Restated Effective November 30, 2023 1. INTRODUCTION The Board of Directors (the “Board”) of Exelixis, Inc. (the “Company”) adopted the Exelixis, Inc. Policy for Recoupment of Variable Compensation on February 28, 2019 (the “Original Policy”) providing for the Company’s recoupment of ce
February 6, 2024	EX-10.24	Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated. Exhibit 10.24 EXELIXIS, INC. CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN Section 1.Introduction. The Exelixis, Inc. Change in Control and Severance Benefit Plan (the “Plan”), established on December 9, 2005, and amended and restated effective December 23, 2008, December 1, 2010, September 6, 2017 and April 28, 2023, is hereby further amended and restated effective December 14, 2023 (the “Effectiv
January 24, 2024	SC 13G/A	EXEL / Exelixis, Inc. / BlackRock Inc. Passive Investment us30161q1040012324.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 17) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2024 EXELIXIS, INC. (E UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 2, 2024 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 8, 2024	EX-99.1	Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024 – Cabozantinib franchise achieves approximately $1.630 billion in preliminary U.S. net product re Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc.
December 20, 2023	EX-3.1	Amended and Restated Bylaws of Exelixis, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF EXELIXIS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II CORPORATE SEAL 1 Section 3. Corporate Seal 1 ARTICLE III STOCKHOLDERS' MEETINGS 1 Section 4. Place of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 4 Section 7. Notice of Meetings 6 Section 8. Quorum 6 Sect
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 14, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
November 1, 2023	EX-10.3	Cash Compensation Information for Non-Employee Directors Exhibit 10.3 EXELIXIS, INC. CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS (as of September 30, 2023) Board of Directors Retainer Fee $60,000 Additional Chair Retainer Fee $35,000 Audit Committee Retainer Fee $15,000 Additional Chair Retainer Fee $15,000 Compensation Committee Retainer Fee $12,000 Additional Chair Retainer Fee $13,000 Nominating and Corporate Governance Committee Retaine
November 1, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 EXELIXIS, INC. ( UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 1, 2023	EX-10.2	Separation Agreement and Release of all Claims dated September 21, 2023, and Consulting Agreement dated September 1 Exhibit 10.2 CONFIDENTIAL SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS This Confidential Separation Agreement and Release of All Claims ("Agreement") is entered into by and between Exelixis, Inc. ("Exelixis") and Vicki L. Goodman, M.D. ("Dr. Goodman"). Dr. Goodman and Exelixis are referred to collectively herein as the Parties. This Agreement will become effective on the eighth (8th) calendar da
November 1, 2023	EX-99.1	Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Conference Call and Webcast Today at 5:00 PM Eastern Time Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $471.9 million, Cabozantinib Franchise U.S. Net Product Revenues of $426.5 million - - Confer
November 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2023 ☐ TRANSITION REPORT PURSUANT Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 29, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of re
November 1, 2023	EX-10.1	Fifth Amendment dated August 24, 2023, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
September 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2023 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File
August 23, 2023	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 23, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
August 1, 2023	EX-99.1	Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces Second Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP
August 1, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 1, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO S Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registr
August 1, 2023	EX-10.1	Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated Exhibit 10.1 EXELIXIS, INC. CHANGE IN CONTROL AND SEVERANCE BENEFIT PLAN SECTION 1. Introduction. The Exelixis, Inc. Change in Control and Severance Benefit Plan (the “Plan”), established on December 9, 2005, and amended and restated effective December 23, 2008, December 1, 2010, and September 6, 2017, is hereby further amended and restated effective April 28, 2023 (the “Effective Date”). The purp
July 24, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2023 EXELIXIS, INC. (Exa UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
June 5, 2023	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
June 2, 2023	SC 13D/A	EXEL / Exelixis Inc / Farallon Capital Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
June 2, 2023	SC 13D/A	EXEL / Exelixis Inc / Caligan Partners LP - EXELIXIS, INC. Activist Investment SC 13D/A 1 p23-1696sc13da.htm EXELIXIS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 2)* Exelixis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of S
May 17, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 15, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☑ Definitive Additional Materials ☐ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 15, 2023	DEFA14A	INVESTOR PRESENTATION Investor Update MAY 2023Forward-Looking Statements This presentation, including any oral presentation accompanying it, contains forward-looking statements, including, without limitation, statements related to: Exelixis’ commitment to creating long-term, sustainable value for shareholders with a disciplined R&D and capital allocation strategy and leveraging the company’s strengths in drug discovery
May 15, 2023	DEFA14A	Schedule 14A DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
May 11, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 9, 2023	EX-99.1	Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.16 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces First Quarter 2023 Financial Results and Provides Corporate Update - Total Revenues of $408.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $363.4 million - - GAAP D
May 9, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 EXELIXIS, INC. (Exact UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 9, 2023	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of regist
May 8, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
May 8, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant þ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement þ Definitive Additional Materials o Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 8, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 8, 2023	EX-99.1	EXELIXIS ANNOUNCES DEPARTURE OF LANCE WILLSEY, M.D. FROM BOARD OF DIRECTORS EXHIBIT 99.1 Investor Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Media Contacts: Jamie Moser / Sharon Stern / Tali Epstein Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 EXELIXIS ANNOUNCES DEPARTURE OF LANCE WILLSEY, M.D. FROM BOARD OF D
May 8, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 3, 2023	DEFC14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 3, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement þ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
May 2, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.
May 2, 2023	EX-2	EX-2 EX-2 EXHIBIT 2 EXELIXIS Exelixis @ExelixisInc Exelixis is successfully helping cancer patients recover stronger and live longer and delivering long-term value for shareholders. To learn more about how you can protect your investment in $EXEL, read today’s press release at bit.ly/3HvJDa6. EXELIXIS R 2:10 PM - May 1, 2023. 11 Views
May 2, 2023	DEFA14A	STOCKHOLDER LETTER 1 Dear Fellow Shareholder, Your Exelixis Board of Directors and management team have been executing a clear and successful strategy to discover, develop and commercialize the next generation of anti-cancer medicines, while creating sustainable shareholder value.
May 2, 2023	EX-1	PROTECT THE VALUE OF YOUR INVESTMENT Vote on the GOLD Proxy Card Today “FOR” Exelixis’ 11 Recommended Director Nominees May 1, 2023 Dear Fellow Shareholder, Your Exelixis Board of Directors and management team have been executing a clear and successf EX-1 EXHIBIT 1 PROTECT THE VALUE OF YOUR INVESTMENT Vote on the GOLD Proxy Card Today “FOR” Exelixis’ 11 Recommended Director Nominees May 1, 2023 Dear Fellow Shareholder, Your Exelixis Board of Directors and management team have been executing a clear and successful strategy to discover, develop and commercialize the next generation of anti-cancer medicines, while creating sustainable shareholder value.
May 1, 2023	DEFC14A	UNITED STATE S SECURITIES AND EXCHANGE COMMISSIO N Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATE S SECURITIES AND EXCHANGE COMMISSIO N Washington, D.
May 1, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 25, 2023	CT ORDER	CT ORDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION April 25, 2023 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Exelixis, Inc.
April 25, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant o Filed by a Party other than the Registrant þ Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Definitive Proxy Statement o Definitive Additional Materials þ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
April 24, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
April 21, 2023	PRRN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
April 17, 2023	PREC14A	UNITED STATE S SECURITIES AND EXCHANGE COMMISSIO N Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Table of Contents UNITED STATE S SECURITIES AND EXCHANGE COMMISSIO N Washington, D.
April 13, 2023	EX-99.1	Exelixis Advances Board Refreshment Plan EXHIBIT 99.1 Investor Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Media Contacts: Jamie Moser / Sharon Stern / Tali Epstein Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 Exelixis Advances Board Refreshment Plan ALAMEDA, Calif. – April 13
April 13, 2023	EX-99.1	Press Release issued by Exelixis, Inc., dated April 13, 2023 EXHIBIT 99.1 Investor Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Media Contacts: Jamie Moser / Sharon Stern / Tali Epstein Joele Frank, Wilkinson Brimmer Katcher 212-355-4449 Exelixis Advances Board Refreshment Plan ALAMEDA, Calif. – April 13
April 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
April 13, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 12, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
April 7, 2023	SC 13D/A	EXEL / Exelixis Inc / Farallon Capital Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
April 6, 2023	PREC14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: þ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
April 6, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin
April 5, 2023	DFAN14A	SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ¨ Filed by a Party other than the Registrant þ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement ¨ Definitive Additional Materials þ Soliciting Material Under Rule 14a-12 Exelixis, Inc.
March 27, 2023	EX-99.2	Form of Nomination Agreement EXHIBIT 99.2 Form of Nomination Agreement ENGAGEMENT AND INDEMNIFICATION AGREEMENT, dated as of March 23, 2023 (this “Agreement”), by and between Farallon Capital Partners, L.P. (“Farallon,” “we” or “us”) and David Johnson (“Nominee” or “you”). WHEREAS, Farallon has asked Nominee, and Nominee has agreed, to be (i) a member of the slate of nominees (the “Slate”) of Farallon or an affiliate thereof
March 27, 2023	SC 13D/A	EXEL / Exelixis Inc / Caligan Partners LP - EXELIXIS, INC. Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. 1)* Exelixis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 30161Q104 (CUSIP Number) David Joh
March 27, 2023	SC 13D/A	EXEL / Exelixis Inc / Farallon Capital Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
March 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 EXELIXIS, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 16, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
March 20, 2023	SC 13D	EXEL / Exelixis Inc / Farallon Capital Partners, L.P. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
March 20, 2023	EX-99.1	Exelixis Announces $550 Million Share Repurchase Program Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Exelixis Announces $550 Million Share Repurchase Program ALAMEDA, Calif. – March 20, 2023 – Exelixis, Inc. (Nasdaq: EXEL) today announced that the company’s Board of Directors has authorized the repu
March 20, 2023	SC 13D	EXEL / Exelixis Inc / Caligan Partners LP - EXELIXIS, INC. Activist Investment SC 13D 1 p23-1145sc13d.htm EXELIXIS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) Under the Securities Exchange Act of 1934 (Amendment No. )* Exelixis, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securit
March 20, 2023	EX-99.1	Joint Filing Agreement PURSUANT TO RULE 13d-1(k) EXHIBIT 99.1 Joint Filing Agreement PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknow
March 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2023 EXELIXIS, INC. (Ex UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 20, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 14, 2023	SC 13G/A	EXEL / Exelixis, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 exel13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) EXELIXIS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30161Q104 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant t
February 13, 2023	SC 13G/A	EXEL / Exelixis, Inc. / RENAISSANCE TECHNOLOGIES LLC Passive Investment SC 13G/A 1 exel-13g20221231.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* EXELIXIS, INC. - (Name of Issuer) Common Stock $.001 Par Value per Share - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 30, 2022 - (Date of Event Which Requires Filing of this Statement) Check the app
February 9, 2023	SC 13G/A	EXEL / Exelixis, Inc. / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 EXELIXIS INC COMMON STOCK Cusip #30161Q104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #30161Q104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 13,044,378 Item 6: 0 Item 7: 13,050,178 Item 8: 0 Item 9: 13,0
February 7, 2023	10-K	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXI
February 7, 2023	EX-10.20	Terms of Employment Offer, dated December 15, 2022, for Dana T. Aftab, Ph.D. Exhibit 10.20 TERMS OF EMPLOYMENT – DANA T. AFTAB (as of December 15, 2022) TITLE: Executive Vice President, Discovery and Translational Research, and Chief Scientific Officer ANNUAL BASE SALARY: $560,000.22 annually BONUS TARGET: 50% of Annual Base salary INITIAL RESTRICTED STOCK UNIT (RSU) AWARD: 100,000 shares of Exelixis, Inc. common stock pursuant to the Exelixis, Inc. 2017 Equity Incentive P
February 7, 2023	EX-10.40	Fourth Amendment dated October 11, 2022, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
February 7, 2023	EX-99.1	EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year 2022 - - Cabozantinib franchise achieved $1.40 bil Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $423.9 million for the Fourth Quarter of 2022, $1.61 billion for the Full Year
February 7, 2023	EX-21.1	Subsidiaries of Exelixis, Inc. Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company, LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 7, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 7, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 26, 2023	SC 13G/A	EXEL / Exelixis, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us30161q1040012623.txt us30161q1040012623.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 16) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
January 20, 2023	SC 13G/A	EXEL / Exelixis, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us30161q1040012023.txt us30161q1040012023.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 15) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d
January 10, 2023	SC 13G/A	EXEL / Exelixis, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 10)* Name of issuer: Exelixis Inc. Title of Class of Securities: Common Stock CUSIP Number: 30161Q104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
January 9, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 8, 2023 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 9, 2023	EX-99.1	Exelixis Announces Preliminary Fourth Quarter and Full Year 2022 Financial Results, Provides 2023 Financial Guidance, and Outlines Key Priorities and Milestones for 2023 – Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc.
December 15, 2022	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 EXELIXIS, INC. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 15, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
November 1, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 1, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
November 1, 2022	EX-10.1	Cash Compensation Information for Non-Employee Directors Exhibit 10.1 CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS Exelixis, Inc. Cash Compensation for Non-Employee Directors Board of Directors Retainer Fee $55,000 Additional Chair Retainer Fee $31,000 Meeting Fee12 $2,500 Audit Committee Retainer Fee $12,000 Additional Chair Retainer Fee $13,000 Meeting Fee13 $1,000 Compensation Committee Retainer Fee $10,000 Additional Chair Retainer Fee $
November 1, 2022	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of re
November 1, 2022	EX-99.1	EXELIXIS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million - - GAAP Diluted EPS of $0.23, Non-GAAP Diluted EPS of $0.31 - - Conference Ca Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES THIRD QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $411.7 million, Cabozantinib Franchise Revenues of $366.5 million - - GAAP Diluted EPS of $0.
September 2, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 2, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
August 9, 2022	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 1, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registra
August 9, 2022	EX-FILING FEES	Filing Fee Table EX-FILING FEES 4 exel20220809s-8ex107feetab.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Exelixis, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered (1) Proposed Maximum Offering Price per Share Proposed Maximum Agg
August 9, 2022	S-8	As filed with the Securities and Exchange Commission on August 9, 2022 As filed with the Securities and Exchange Commission on August 9, 2022 Registration No.
August 9, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 9, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
August 9, 2022	EX-10.2	Cash Compensation Information for Non-Employee Directors Exhibit 10.2 CASH COMPENSATION INFORMATION FOR NON-EMPLOYEE DIRECTORS Exelixis, Inc. Cash Compensation for Non-Employee Directors Board of Directors Retainer Fee $55,000 Additional Chair Retainer Fee $31,000 Meeting Fee12 $2,500 Audit Committee Retainer Fee $12,000 Additional Chair Retainer Fee $13,000 Meeting Fee13 $1,000 Compensation Committee Retainer Fee $10,000 Additional Chair Retainer Fee $
August 9, 2022	EX-99.1	EXELIXIS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million - - GAAP Diluted EPS of $0.22, Non-GAAP Diluted EPS of $0.28 - - Conference C Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $419.4 million, Cabozantinib Franchise Revenues of $347.0 million - - GAAP Diluted EPS of $0
August 9, 2022	EX-10.3	Seventh Amendment dated May 16, 2022, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC and Exelixis, Inc. Exhibit 10.3 SEVENTH AMENDMENT TO LEASE AGREEMENT THIS SEVENTH AMENDMENT TO LEASE AGREEMENT (this ?Amendment?) is made and entered into as of May 16, 2022, by and between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company (?Landlord?), and EXELIXIS, INC. a Delaware corporation (?Tenant?). RECITALS A.Landlord (as successor in interest to Ascentris 105, LLC, a Colorado limited
August 9, 2022	EX-10.1	Exelixis, Inc. 2017 Equity Incentive Plan Exhibit 10.1 Exelixis, Inc. 2017 Equity Incentive Plan Adopted by the Board of Directors: February 23, 2017 Amended by the Compensation Committee: March 22, 2017 Approved by the Stockholders: May 24, 2017 Amended by the Company: December 18, 2017 Amended by the Compensation Committee: March 18, 2020 Approved by the Stockholders: May 20, 2020 Amended by the Board of Directors: April 1, 2022 Approve
July 19, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 18, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
May 27, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 25, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 10, 2022	EX-10.2	Second Amendment dated May 7, 2019, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 10, 2022	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 1, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registr
May 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 10, 2022	EX-99.1	EXELIXIS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million - - GAAP Diluted EPS of $0.21, Non-GAAP Diluted EPS of $0.26 - - Conference Ca Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES FIRST QUARTER 2022 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $356.0 million, Cabozantinib Franchise Revenues of $310.3 million - - GAAP Dilut
May 10, 2022	EX-10.1	Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 2, 2022	CT ORDER	CT ORDER
April 14, 2022	DEF 14A	Schedule 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 14, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin
April 13, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
February 23, 2022	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 23, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 18, 2022	EX-21.1	Subsidiaries of Exelixis, Inc. Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis Patent Company, LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 18, 2022	10-K	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXI
February 18, 2022	EX-10.1	Form of Indemnification Agreement Exhibit 10.1 EXELIXIS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of , 20 and is between Exelixis, Inc., a Delaware corporation (the ?Company?), and (?Indemnitee?). Recitals A. Indemnitee?s service to the Company substantially benefits the Company, and given the nature of such services, the general protections provided to Indemnitee by applicable l
February 18, 2022	EX-10.42	Third Amendment dated December 10, 2021, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS Exhibit 10.42 Confidential Execution Version THIRD AMENDMENT TO SUPPLY AGREEMENT This Third Amendment to the Supply Agreement (the ?Amendment?) is entered into as of 10 December, 2021 (the ?Amendment Effective Date?) by and between Exelixis, Inc., a Delaware company having an address at 1851 Harbor Bay Parkway, Alameda CA 94502, USA (?Exelixis?) and Ipsen Pharma SAS, a French corporation having an
February 18, 2022	EX-10.18	Offer Letter Agreement, dated Exhibit 10.18 December 2, 2021 Vicki L. Goodman, M.D. Dear Vicki: We are proud to invite you to join our team. Our offer of employment is to join Exelixis, Inc. (the ?Company?). Your title will be that of Executive Vice President, Product Development and Medical Affairs and Chief Medical Officer, in our Development Administration department reporting to Michael Morrissey, President and Chief Execu
February 18, 2022	EX-4.2	Description of the Common Stock of Exelixis, Inc. Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, as amended Exhibit 4.2 DESCRIPTION OF THE COMMON STOCK OF EXELIXIS, INC. REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED Description of Capital Stock The authorized capital stock of Exelixis, Inc. (Exelixis, we, our or us) consists of 400,000,000 shares of common stock, $0.001 par value, and 10,000,000 shares of preferred stock, $0.001 par value. A description of material
February 17, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 17, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 17, 2022	EX-99.1	EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for the Full Year 2021 - - Cabozantinib franchise achieved a signifi Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $451.1 Million for the Fourth Quarter of 2021, $1.43 Billion for
February 14, 2022	SC 13G/A	EXEL / Exelixis, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) EXELIXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30161Q104 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fi
February 11, 2022	SC 13G/A	EXEL / Exelixis, Inc. / RENAISSANCE TECHNOLOGIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* EXELIXIS, INC. - (Name of Issuer) Common Stock $.001 Par Value per Share - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 10, 2022	SC 13G/A	EXEL / Exelixis, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 9)* Name of issuer: Exelixis Inc. Title of Class of Securities: Common Stock CUSIP Number: 30161Q104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ??Rule
February 9, 2022	SC 13G	EXEL / Exelixis, Inc. / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 EXELIXIS INC COMMON STOCK Cusip #30161Q104 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #30161Q104 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 668,676 Item 6: 0 Item 7: 18,804,979 Item 8: 0 Item 9: 18,804,979 Item 11: 5.943% I
January 27, 2022	SC 13G/A	EXEL / Exelixis, Inc. / BlackRock Inc. Passive Investment us30161q1040012722.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 14) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 26, 2022	SC 13G/A	EXEL / Exelixis, Inc. / BlackRock Inc. Passive Investment us30161q1040012522.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 13) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 10, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2022 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Num
January 10, 2022	EX-99.1	Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022 — Corporate priorities for 2022 include initial readout of up to three cabozanti Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc.
December 17, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 16, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
November 2, 2021	EX-99.1	EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million - - GAAP Diluted EPS of $0.12, Non-GAAP Diluted EPS of $0.20 - - Conference Ca Exhibit 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $328.4 Million, Cabozantinib Franchise Revenues of $263.1 Million - - GAAP Dilut
November 2, 2021	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 1, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of regis
November 2, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
October 5, 2021	CT ORDER	CT ORDER
August 5, 2021	EX-4.1	Specimen Common Stock Certificate. THIS CERTIFIES THAT is the owner of CUSIP DATED COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.
August 5, 2021	10-Q	Table of Contents Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 2, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registra
August 5, 2021	EX-3.1	Restated Certificate of Incorporation of Exelixis, Inc. Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF EXELIXIS, INC. Exelixis, Inc., a Delaware corporation, hereby certifies that: 1. The present name of the corporation is Exelixis, Inc. The corporation was incorporated under the name "Exelixis Pharmaceuticals, Inc.? by filing its original Certificate of Incorporation with the Secretary of State of the State of Delaware on November 15, 1994. 2. A
August 5, 2021	EX-99.1	EXELIXIS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $385.2 Million, Cabozantinib Franchise Revenues of $284.2 Million - - GAAP Diluted EPS of $0.30, Non-GAAP Diluted EPS of $0.37 - - Raised Net P Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $385.2 Million, Cabozantinib Franchise Revenues of $284.2 Million - - GAAP Diluted EPS of $0
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 5, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numb
June 21, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
June 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
June 16, 2021	CT ORDER	CT ORDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 16, 2021 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Exelixis, Inc.
June 16, 2021	CT ORDER	CT ORDER UNITED STATES SECURITIES AND EXCHANGE COMMISSION June 16, 2021 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 Exelixis, Inc.
May 27, 2021	8-K	Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 26, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number
May 11, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 7, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 6, 2021	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 2, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of registr
May 6, 2021	EX-10.2	First Amendment dated December 20, 2016, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 6, 2021	EX-10.3	Second Amendment dated September 14, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (i) NOT MATERIAL AND (ii) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 6, 2021	EX-10.1	Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 6, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 6, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Number)
May 6, 2021	EX-99.1	EXELIXIS ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $270.2 Million, Cabozantinib Franchise Revenues of $227.2 Million - - Conference Call and Webcast Today at 5:00 PM Eastern Time - EXHIBIT 99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES FIRST QUARTER 2021 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $270.2 Million, Cabozantinib Franchise Revenues of $227.2 Million - - Conference
May 6, 2021	EX-10.4	Third Amendment dated October 26, 2017, to the Collaboration and License Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 6, 2021	EX-10.6	First Amendment dated October 26, 2017, to the Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
May 6, 2021	EX-10.5	Supply Agreement dated February 29, 2016, by and between Exelixis, Inc. and Ipsen Pharma SAS [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
April 15, 2021	DEF 14A	- DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14
April 15, 2021	DEFA14A	- DEFA14A DEFA14A 1 d33710ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p
March 5, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 4, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Numbe
March 3, 2021	8-K	Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Material Modification to Rights of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 25, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
March 3, 2021	EX-3.1	Amended and Restated Bylaws of Exelixis, Inc. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF EXELIXIS, INC. (A DELAWARE CORPORATION) ARTICLE I Offices 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II Corporate Seal 1 Section 3. Corporate Seal 1 ARTICLE III Stockholders? Meetings 1 Section 4. Place Of Meetings 1 Section 5. Annual Meetings 1 Section 6. Special Meetings 2 Section 7. Notice Of Meetings 5 Section 8. Quorum 5 Sect
February 16, 2021	SC 13G	SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) EXELIXIS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 30161Q104 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fil
February 11, 2021	EX-10.11	Form of Stock Option Agreement under the Exelixis, Inc. 2017 Equity Incentive Plan Exhibit 10.11 EXELIXIS, INC. 2017 Equity Incentive Plan Option Agreement (Incentive Stock Option or Nonstatutory Stock Option) Pursuant to your Notice of Grant of Stock Option (“Grant Notice”) and this Option Agreement and in consideration of your services, Exelixis, Inc. (the “Company”) has granted you an option under its 2017 Equity Incentive Plan (the “Plan”) to purchase the number of shares of
February 11, 2021	EX-21.1	Subsidiaries of Exelixis, Inc. Exhibit 21.1 SUBSIDIARIES OF EXELIXIS, INC. Name of Subsidiary State or Other Jurisdiction of Incorporation or Organization Exelixis International (Bermuda) Ltd. Bermuda Exelixis Patent Company, LLC Delaware Exelixis Plant Sciences, Inc. Delaware Exelixis U.S., LLC Delaware
February 11, 2021	SC 13G/A	SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* EXELIXIS, INC. - (Name of Issuer) Common Stock $.001 Par Value per Share - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru
February 11, 2021	EX-10.32	Sixth Amendment dated December 11, 2020, to Lease Agreement dated May 2, 2017, between SCG Harbor Bay Parkway Phase I, LLC (as successor in interest to Waterfront EDP, LLC) and Exelixis, Inc. Exhibit 10.32 SIXTH AMENDMENT TO LEASE AGREEMENT THIS SIXTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is made and entered into as of December 11, 2020, by and between SCG HARBOR BAY PARKWAY PHASE I, LLC, a Delaware limited liability company (“Landlord”), and EXELIXIS, INC. a Delaware corporation (“Tenant”). RECITALS A. Landlord (as successor in interest to Ascentris 105, LLC, a Colorado limi
February 11, 2021	10-K	Annual Report - 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended January 1, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-30235 EXELIXIS,
February 10, 2021	EX-99.1	EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $270.1 Million for the Fourth Quarter of 2020, $987.5 Million for the Full Year 2020 - - GAAP Diluted EPS of $0.09 for the Fourth EX-99.1 2 exel20201231exhibit991.htm EX-99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $270.1 Million for the Fourth Qua
February 10, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 10, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File N
February 10, 2021	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 8)* Name of issuer: Exelixis Inc. Title of Class of Securities: Common Stock CUSIP Number: 30161Q104 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule
February 5, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 3, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 27, 2021	SC 13G/A	SC 13G/A us30161q1040012621.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 12) EXELIXIS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 30161Q104 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic
January 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2021 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
January 11, 2021	EX-99.1	EXELIXIS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS, PROVIDES 2021 FINANCIAL GUIDANCE, AND OUTLINES KEY PRIORITIES AND ANTICIPATED MILESTONES FOR 2021 – Cabozantinib Franchise Preliminary Net Product Revenue of $200 mil EX-99.1 2 a210110corporatepriorities.htm EX-99.1 Investor Contacts: Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Media Contact: Hal Mackins For Exelixis, Inc. 415-994-0040 [email protected] EXELIXIS ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL
November 5, 2020	EX-10.1	Third Amendment dated September 3, 2020, to the Collaboration and License Agreement dated January 30, 2017, by and between Exelixis, Inc. and Takeda Pharmaceutical Company Limited [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.
November 5, 2020	EX-99.1	EXELIXIS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $231.1 Million, Cabozantinib Franchise Revenues of $168.6 Million - - GAAP Diluted EPS of $(0.10), Non-GAAP Diluted EPS of $0.04 - - Conference EX-99.1 2 exel20200930exhibit991.htm EX-99.1 Contacts: Chris Senner Chief Financial Officer Exelixis, Inc. 650-837-7240 [email protected] Susan Hubbard EVP, Public Affairs & Investor Relations Exelixis, Inc. 650-837-8194 [email protected] EXELIXIS ANNOUNCES THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - Total Revenues of $231.1 Million, Cabozantinib Franchise Revenues
November 5, 2020	10-Q	Quarterly Report - 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 2, 2020 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-30235 EXELIXIS, INC. (Exact name of regis
November 5, 2020	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 5, 2020 EXELIXIS, INC. (Exact name of registrant as specified in its charter) Delaware 000-30235 04-3257395 (State or Other Jurisdiction of Incorporation) (Commission File Nu
August 6, 2020	EX-10.2	Exelixis, Inc. 2016 Inducement Award Plan EX-10.2 3 exel20200630exhibit102.htm EXHIBIT 10.2 Exhibit 10.2 EXELIXIS, INC. 2016 INDUCEMENT AWARD PLAN ADOPTED BY THE BOARD OF DIRECTORS: NOVEMBER 18, 2016 AMENDED BY THE COMPANY: APRIL 12, 2018 AMENDED BY THE COMPENSATION COMMITTEE: DECEMBER 6, 2018 AMENDED BY THE COMPENSATION COMMITTEE: MAY 6, 2020 1. GENERAL. (a) Eligible Award Recipients. Awards under the Plan may only be granted to Employee

GB:0IJO	51,00 $
DE:EX9	43,88 €
IT:1EXEL	45,30 €

EXEL / Exelixis, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings